目的：分析血浆微小核糖核酸(miR)-93和miR21联合检测对2型糖尿病视网膜病变(DR)进展的预测价值。

方法：选取本院2013-06/2014-06收治的2型DR患者76例，根据随访结果，将患者分成DR非进展组(34例)和DR进展组(42例)，另选取45例健康体检者为对照组。检测三组血清中miR93和miR21水平的变化； 分析DR患者预后的独立危险因素； 分析其对患者预后的预测价值。

结果：DR进展组患者血清中miR93和miR21水平明显高于DR非进展组和对照组(均P<0.01)； 二者可作为影响DR患者病情进展的独立危险因素； 两者联合检测曲线下面积、特异度与敏感度均高于单独检测(P<0.05)。

结论：miR93和miR21在DR患者血清中增高，影响DR患者病情进展。

METHODS: Totally 76 patients with type 2 diabetic retinopathy admitted to our hospital from June 2013 to June 2014 were divided into DR non-progressive group(34 cases)and DR progressive group(42 cases)according to the follow-up results, and 45 healthy people were selected as the control group. The serum levels of miR93 and miR21 in three groups were detected; the independent risk factors of prognosis in DR patients were analyzed; and the predictive value of miR93 and miR21 in DR patients was analyzed.

RESULTS: The serum levels of miR93 and miR21 in DR progressive group were significantly higher than those in non-progressive group and control group(all P< 0.01); both of them could be used as independent risk factors affecting the progress of DR patients; the area, specificity and sensitivity under the combined detection curve were higher than those of single detection(P<0.05).

CONCLUSION: The serum levels of miR93 and miR21 are increased in DR patients, which can affect the progress of DR patients, and can be used as biomarkers for the diagnosis of DR.